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Abstract
An organization that effectively manages knowledge should be able to recognize and
proactively apply new learnings to better anticipate risks. This is particularly important in the
manufacture of medicinal products. Since the publication of ICH Q10 in 2010, Quality Risk
Management (QRM) and Knowledge Management (KM) have been positioned as co-enablers
to the Pharmaceutical Quality System. The authors of this paper present a Knowledge
Management process model to foster greater practical understanding of the practice of
knowledge management. This model when joined with the familiar ICH Q9 process model for
QRM, should enable a company to better manage their knowledge and risk. In addition, a
framework, the Risk-Knowledge Infinity Cycle is presented to better link these two disciplines
at large and specifically as the dual enablers to ICH Q10. It is the authors belief that treating
QRM and KM in this way will have a variety of potential benefits for biopharmaceutical
companies, including improved risk-based decision making, facilitating evidence-based risk
reduction and increased process knowledge, leading to less uncertainty and subjectivity in
QRM outputs. This should ultimately result in more effective risk-based control strategies
and more reliable manufacturing processes, which potentially lead to increased protection and other benefits including product availability and value - for patients. This paper presents
the Knowledge Management process model, and the Risk-Knowledge Infinity Cycle and an
example of the application of the Risk-Knowledge Infinity Cycle.
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1. Introduction
Since the introduction of ICH Q10 [1], the two enablers to the Pharmaceutical Quality System
(PQS) being Quality Risk Management (QRM) and Knowledge Management (KM) have been
treated as distinct and largely disconnected from each other in research and in practice.
As part of a research effort by Lipa, O’Donnell and Greene, a key focus has been to unify QRM
and KM in support of a more effective PQS and ultimately enhancing protection of the patient
through improved quality risk management outcomes. This research included a detailed
literature review of how other industries link knowledge management and risk management,
as well as an examination of the regulatory guidance on managing knowledge and risk
relevant to the biopharmaceutical industry [2].
The purpose of this paper is to provide an introduction to a model to enhance the practical
understanding of KM in the manner which QRM benefits from the process model depicted in
ICH Q9 [3]. This model is presented as the Knowledge Management process model.
Subsequently, a framework to better describe the link between KM and QRM is presented,
the Risk-Knowledge Infinity Cycle. Further detail on both this model and framework will be
the subject of a subsequent publication in the Institute of Validation Technology [4] and
Level3, a Technological University Dublin publication [5].

2. Knowledge Management Process Model
A Knowledge Management process model, which illustrates the role of KM in how an
organization can manage its knowledge as an asset, is proposed by the authors and is
presented here in (Figure 1).
The model can be viewed as a KM analogue to the QRM process model presented in ICH Q9
[3]. It encompasses the rather narrow definition of KM proposed by ICH Q10, being “a
systematic approach to acquiring, analysing, storing, and disseminating information related
to products, manufacturing processes and components,” and further enhances this definition
by highlighting the need for knowledge to flow in to KM from various processes and to
subsequently be applied to various processes in support of decisions or other objectives. The
model also features the need for KM practices to facilitate the management of both explicit
and tacit knowledge, and channels for knowledge communication, exchange and sharing
supported by a knowledge culture.

3

Illustrative processes

Development
Studies

CPV
QRM

Change
Management

Technology
Transfer

…

Knowledge Creation
Newly acquired knowledge
(product, process & platform knowledge)

Knowledge Identification,
Review & Analysis
Basis for prior knowledge

Knowledge
Dissemination
Knowledge Storage & Visibility

Knowledge Availability

(product, process & platform knowledge)

Knowledge Capture

Knowledge Management Practices
for both explicit and tacit knowledge

Knowledge communication,
exchange & sharing (via knowledge culture)

Knowledge Curation

Growing and evolving knowledge

Knowledge Management

Knowledge Application, Growth & Transfer
QRM

Product
Filing

Technology
Transfer

Change
Management

CAPA
…
Illustrative processes

DECISION
© Lipa & O’Donnell 2020

(CPV = continuing process verification | CAPA = Corrective Actions Preventative Actions)
Figure 1 – Knowledge Management process model

There are several important features to this model which have the opportunity to better
define how KM can be practically applied. These features will be discussed in subsequent
publications as previously detailed.
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3. Risk-Knowledge Infinity Cycle
Building on the detailed literature review and the two concepts established in a previously
published paper by the authors in the Journal of Validation Technology [2], a simple
framework was developed to link Risk and Knowledge. The first underlying concept is that
knowledge in both an input and an output to risk management [2] . The second concept is
that knowledge has an inverse relationship with risk, such that the more knowledge one has,
the less uncertainty and therefore, the less risk [2, 6]. This proposed simple framework,
entitled the Risk-Knowledge Infinity Cycle is presented in Figure 2, and provides a visualization
of how risk and knowledge are connected.
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Figure 2 – The Risk-Knowledge Infinity Cycle

In order to present an example of the application of this Risk-Knowledge Infinity Cycle, the
authors applied the framework to ICH Q10, as illustrated in Figure 3, which depicts the how
QRM and KM become related in maximizing the knowledge available to in turn minimize risk.
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ACQUIRE, GROW, CAPTURE &
RETAIN NEW KNOWLEDGE

Figure 3 – The Risk-Knowledge Infinity Cycle applied to ICH Q10
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There are several important features to this framework, its symbolism and practical
application to ICH Q10, including an example to a sterile filling line, which will be discussed in
subsequent publications as previously detailed.

4. Conclusion
The authors envision a unified approach to managing knowledge and risk as a foundation to
the PQS as depicted in Figure 4.
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Figure 4 - A Re-framed and Unified PQS foundation

On achieving this vision, QRM and KM together can better support each of the four PQS
elements and have the potential to deliver additional benefit, including achieving true riskbased control strategies, evidence-based risk reduction and more. These benefits and
additional advantages will be further explored and published separately.

Disclaimer
The views expressed in this article are those of the authors and are not necessarily those of
the Health Products Regulatory Agency (HPRA) or Merck & Co., Inc. (Kenilworth, NJ USA).
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